JP2022536698A - 細胞老化活性化化合物 - Google Patents
細胞老化活性化化合物 Download PDFInfo
- Publication number
- JP2022536698A JP2022536698A JP2021573470A JP2021573470A JP2022536698A JP 2022536698 A JP2022536698 A JP 2022536698A JP 2021573470 A JP2021573470 A JP 2021573470A JP 2021573470 A JP2021573470 A JP 2021573470A JP 2022536698 A JP2022536698 A JP 2022536698A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group selected
- synthesis
- guayuline
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 132
- 230000009758 senescence Effects 0.000 title description 6
- 230000003213 activating effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 70
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 17
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 16
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 13
- 241000282414 Homo sapiens Species 0.000 claims abstract description 8
- 230000032683 aging Effects 0.000 claims abstract description 8
- RBRKRLQNZMJOLD-VXNHWSESSA-N CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CCC(=O)C4(C)C Chemical compound CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CCC(=O)C4(C)C RBRKRLQNZMJOLD-VXNHWSESSA-N 0.000 claims abstract description 5
- CGCTVTOHSPHPNF-UHFFFAOYSA-N argentatin A Natural products CC(C)(O)C(O)CCC(C)(O)C1C(O)CC2(C)C3CCC4C(C)(C)C(CCC45CC35CCC12C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O CGCTVTOHSPHPNF-UHFFFAOYSA-N 0.000 claims abstract description 5
- RBRKRLQNZMJOLD-UHFFFAOYSA-N beta-Mono-Me ester ‘«Ù(Z)-Aconitic acid Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CCC34CC4(CCC(=O)C4(C)C)C4CCC3C2(C)CC1O RBRKRLQNZMJOLD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000010171 animal model Methods 0.000 claims abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 4
- 231100000024 genotoxic Toxicity 0.000 claims abstract description 4
- 230000001738 genotoxic effect Effects 0.000 claims abstract description 4
- 238000001727 in vivo Methods 0.000 claims abstract description 4
- AHOBTXNYSMZYDP-UHFFFAOYSA-N argentatin C Natural products CC(CCC(O)C(C)(C)O)C1C(O)CC2(C)C3CCC4C(C)(C)C(=O)CCC45CC35CCC12C AHOBTXNYSMZYDP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 230000004054 inflammatory process Effects 0.000 claims abstract description 3
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 230000015572 biosynthetic process Effects 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 29
- 238000003786 synthesis reaction Methods 0.000 claims description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000012074 organic phase Substances 0.000 claims description 20
- 239000011541 reaction mixture Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- 229960000583 acetic acid Drugs 0.000 claims description 14
- 230000010094 cellular senescence Effects 0.000 claims description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
- 230000006698 induction Effects 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 238000004440 column chromatography Methods 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 229930187083 argentatin Natural products 0.000 claims description 7
- 230000007246 mechanism Effects 0.000 claims description 7
- 239000012362 glacial acetic acid Substances 0.000 claims description 6
- 150000002923 oximes Chemical class 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 235000019439 ethyl acetate Nutrition 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- IMZLIOGSDVHHAJ-UHFFFAOYSA-N argentatin D Natural products C12C(C)CCC(C(C)(C)O)OC2CC2(C)C1(C)CCC13CC3(CCC(O)C3(C)C)C3CCC12 IMZLIOGSDVHHAJ-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 229940117975 chromium trioxide Drugs 0.000 claims description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- WJCXADMLESSGRI-UHFFFAOYSA-N phenyl selenohypochlorite Chemical compound Cl[Se]C1=CC=CC=C1 WJCXADMLESSGRI-UHFFFAOYSA-N 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 239000012047 saturated solution Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- 239000012265 solid product Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 4
- 230000005907 cancer growth Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 231100000065 noncytotoxic Toxicity 0.000 abstract 1
- 230000002020 noncytotoxic effect Effects 0.000 abstract 1
- 231100000804 nongenotoxic Toxicity 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 50
- 230000000694 effects Effects 0.000 description 29
- 238000000034 method Methods 0.000 description 25
- 230000003442 weekly effect Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 108010017842 Telomerase Proteins 0.000 description 15
- 210000003411 telomere Anatomy 0.000 description 15
- 108091035539 telomere Proteins 0.000 description 15
- 102000055501 telomere Human genes 0.000 description 15
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 14
- 229960004316 cisplatin Drugs 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 108050006400 Cyclin Proteins 0.000 description 8
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 7
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- LOVYCUYJRWLTSU-UHFFFAOYSA-N 2-(3,4-dichlorophenoxy)-n,n-diethylethanamine Chemical group CCN(CC)CCOC1=CC=C(Cl)C(Cl)=C1 LOVYCUYJRWLTSU-UHFFFAOYSA-N 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 241001495453 Parthenium argentatum Species 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical class O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 230000025084 cell cycle arrest Effects 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 150000003648 triterpenes Chemical class 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- BRSJEZNEKATFHB-UHFFFAOYSA-N argentatin B Natural products CC1CCCC(OC2CC3(C)C4CCC5C(C)(C)C(=O)CCC56CC46CCC3(C)C12)C(C)(C)O BRSJEZNEKATFHB-UHFFFAOYSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- KCYOWUNRFWIOTH-UHFFFAOYSA-N dethio-tetra(methylthio)chetomin Natural products C12C(C)CCC(C(C)(C)O)OC2CC2(C)C1(C)CCC13CC3(CCC(=O)C3(C)C)C3CCC12 KCYOWUNRFWIOTH-UHFFFAOYSA-N 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000008844 regulatory mechanism Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- BSLYZLYLUUIFGZ-JRUDBKCSSA-N 4,4,14-trimethyl-9,19-cyclo-5alpha,9beta-cholestane Chemical compound C1CCC(C)(C)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]3(C)[C@@H]1CC2 BSLYZLYLUUIFGZ-JRUDBKCSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 231100000310 mutation rate increase Toxicity 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- PWVRXSQPCQPQHM-UHFFFAOYSA-N 2-(4-aminophenyl)-1h-indol-6-amine Chemical compound C1=CC(N)=CC=C1C1=CC2=CC=C(N)C=C2N1 PWVRXSQPCQPQHM-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- QKHYXKLHIXEAGP-UHFFFAOYSA-N Partheniol Natural products CC(=C)C1CCC(C)(O)C2CC=C(C)C2C1 QKHYXKLHIXEAGP-UHFFFAOYSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DYXWUZXSAMLWND-UHFFFAOYSA-N partheniol Natural products OC1CC(C)=CCCC(C)=CC2C(C)(C)C12 DYXWUZXSAMLWND-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003521 tetracyclic triterpenoids Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
- C07C59/82—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings the keto group being part of a ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Description
本発明は、医薬品化学の分野、特に天然起源の化合物の治療効果に関する。
がんは、現在、世界規模で最も危惧される疾患の1つであり、疾患が課す経済的及び社会的側面に起因して、特に開発途上国の公衆衛生システムにとって課題である。
本発明は、健常細胞に対する抗増殖性効果を引き起こさないことが間接的に示されている、細胞周期の調節機構に対して作用するという事実に起因して無毒性である、式(I)及び(I’)の化合物の重要且つ新規な抗腫瘍活性に関する。化合物(1)は、式:
(A)-(B)-(C)
(式中、
Aは、
の1つから選択される基であり、
Bは、
であり、及び
Cは、
の1つから選択される基であり、
ここで、R1は、
から選択される基を表し、
R2は、
から選択される基を表し、
R3は、
から選択される基を表し、
R4は、-OH、
から選択される基を表し、
R1及びR3は、同時に、
であり得、
R3及びR4は、同時に、-OH又は-OAcであり得、
R1及びR2は、同時に、それぞれ
及び-Brであることはなく、
R5は、H、CH3又はアルキル鎖の1つから選択される基であり、
Aが、
であるとき、R1は、
ではなく、且つR2は、-Brではなく、且つR3及びR4は、同時に、-OH又は-OAcから選択される基であり、
Cが、
であるとき、R1及びR3は、同時に=Oであり得、及びR2は、-Brではないか、又は
Aが、
であるとき、R1及びR2は、一緒に、基
を形成し得る)
並びに上記の化合物の鏡像異性体、ジアステレオ異性体、鏡像異性体の混合物、ジアステレオ異性体の混合物、アノマー、水和物、溶媒和物、多形体及びその薬学的に許容できる塩を有する。
(A)-(B)-(C)
(式中、
A、B、R1、R2、R3、R4及びR5は、上記で定義された意味を有するが、但し、
R3及びR4は、同時に-OHであり得ず、及び
R1及びR2は、同時に、それぞれ=O及び-Hであることはないことを条件とする)
並びに上記の化合物の鏡像異性体、ジアステレオ異性体、鏡像異性体の混合物、ジアステレオ異性体の混合物、アノマー、水和物、溶媒和物、多形体及びその薬学的に許容できる塩が好ましい。
Aは、基
であり、
Bは、基
であり、
Cは、基
であり、
ここで、R1は、基:=Oを表し、
R2は、基:-Hを表し、
R3は、-OHから選択される基を表し、
R4は、-OHから選択される基を表す、化合物及び/又は上記の化合物の鏡像異性体、ジアステレオ異性体、鏡像異性体の混合物、ジアステレオ異性体の混合物、アノマー、水和物、溶媒和物、多形体及びその薬学的に許容できる塩である。
(A)-(B)-T
(式中、
A及びBは、上記で定義された意味を有し、
R1は、=O、
から選択される基を表し、
R2は、
から選択される基を表し、
R3は、
から選択される基を表し、
R1及びR3は、同時に=Oであり得、
R1及びR2は、同時に、それぞれ
及び-Brであることはなく、
R5は、H、CH3又はアルキル鎖の1つから選択される基であり、
Aが、
であるとき、R1は、
ではなく、及びR2は、-Brではなく、
Aが、
であるとき、R1及びR2は、一緒に、基
を形成し得、Tは、基
を表す)
並びに上記の化合物の鏡像異性体、ジアステレオ異性体、鏡像異性体の混合物、ジアステレオ異性体の混合物、アノマー、水和物、溶媒和物、多形体及びその薬学的に許容できる塩が好ましい。
化合物(Ia)の合成
100mgのInを5mLの氷酢酸に溶解させ、酢酸中の0.4mLの臭素の1M溶液と反応させた。反応は、撹拌下において3℃で実施した。1.25時間後、反応混合物を、50gの氷を含むエルレンマイヤーフラスコに注いだ。大量の沈殿物の存在が認められ、それを5%NaHCO3溶液で洗浄し、及びその後、再結晶化して生成物Iaを得た(94%)。P.f.116~118℃.IR(フィルム)Vmax cm-1:3380.48(O-H),2972.39-2872.9(C-H),1721.94(C=O),1463.42,1382.14.EMIE m/z(%):550(M+,0.77),498(15),496(15),351(5),349(5),143(100),125(30),107(31),81(20),71(32),43(30)。RMN 1H(200MHz,CDCl3)δppm:0.60(d,J=4.3,1H,H-19),0.73(d,J=4.3,1H,H-19’),0.89(s,3H,CH3),1.14(s,3H,CH3),1.16(s,6H,2CH3),1.25(s,3H,CH3),1.29(s,3H,CH3),2.70(sa,2H,2O-H),3.86(t,J=7.7,1H,H-24),4.63(m,1H,H-16),5.11(dd,J=6.5,J=12.8,1H,H-2β).RMN 13C(75MHz,CDCl3)δppm:32.9(C-1),37.6(C-2),201.4(C-3),50.9(C-4),47.7(C-5),21.01(C-6),25.6(C-7),43.5(C-8),20.8(C-9),25.9(C-10),26.6(C-11),31.8(C-12),46.2(C-13),46.5(C-14),48.3(C-15),73.2(C-16),55.4(C-17),21.6(C-18),30.2(C-19),87.0(C-20),21.1(C-21),37.3(C-22),27.3(C-23),84.5(C-24),70.9(C-25),27.3(C-26),26.1(C-27),20.4(C-28),20.7(C-29),21.0(C-30).
EtOAc(4.6ml)中のIn(200mg)及び塩化フェニルセレン(120mg)の溶液を室温で2時間にわたって撹拌した。その後、1mLの水を撹拌しながら反応混合物に添加した。水相を分離し、且つ2mLのTHF及び0.2mLの30%H2O2を添加した。得られた混合物を室温で1時間にわたって撹拌した。その時点後、反応を従来の方法によって処理し、及び不純な固体を得た。固体をカラムクロマトグラフィーによって精製して、140mg(70%)の所望の生成物を融点196~198℃の結晶性固体として得た。IR(フィルム)Vmax cm-1:3380.47(O-H),2967.73,2873.35,1667.21(C=O),1463.32,1379.72。EM-IE m/z(%):470(M+,1),452(12),434(7),411(2),143(100),125(25),107(10),59(10).RMN 1H(200MHz,CDCl3)δppm:0.81(d,J=4.6,1H,H-19),0.90(s,3H,CH3),0.97(s,3H,CH3),1.11(s,3H,CH3),1.15(s,3H,CH3),1.26(s,3H,CH3),1.30(s,3H,CH3),1.42(s,3H,CH3),3.86(t,J=7.6,1H,H-24),4.61(m,1H,H-16),5.94(d,J=10.0,1H,H-2),6.77(d,J=10.0,1H,H-1).RMN 13C(75.4MHz,CDCl3)δppm:153.7(C-1),126.7(C-2),205.1(C-3),47.015(C-4),44.9(C-5),19.7(C-6),27.6(C-7),44.5(C-8),24.1(C-9),29.9(C-10),24.0(C-11),32.8(C-12),46.1(C-13),46.3(C-14),47.6(C-15),73.2(C-16),55.5(C-17),21.5(C-18),30.8(C-19),87.2(C-20),25.5(C-21),37.5(C-22),23.8(C-23),84.5(C-24),70.9(C-25),27.3(C-26),26.1(C-27),19.8(C-28),20.1(C-29),19.1(C-30).
25.5mgの誘導体Ib、21mgの酢酸ナトリウム及び2mLの酢酸無水物の混合物を還流温度で1時間にわたって加熱した。その後、混合物を、5gの氷を含むエルレンマイヤーフラスコに注ぎ、及び3分間にわたって撹拌した。フラスコの内容物をAcOEt(3×)で抽出した。有機相を減圧下で乾燥及び濃縮して半固体を得た。前記生成物を再結晶化(ヘキサン/AcOEt)して、158~160℃の融点を有する27.4mgの酢酸Ic(99%)を得た。IR(フィルム)cm-1:2971.64,2937.91,2873.33,1734.33(C=O),1668.83(C=O),1460.83,1367.44,1241.0,755.46。RMN 1H(300MHz,CDCl3)δppm:0.95(s,3H,CH3),1.10(s,3H,CH3),1.22(s,3H,CH3),1.25(s,6H,2CH3),1.47(s,3H,CH3),1.55(s,3H,CH3),1.99(s,3H,CH3),2.03(s,3H,CH3),2.54(d,J=8.49,1H),3.74(t,J=7.9,1H,H-24),5.40(m,1H,H-16),5.95(d,J=10,1H,H-2),6.77(d,J=10,1H,H-1).RMN 13C(75.4MHz,CDCl3)δppm:153.5(C-1),126.9(C-2),205.1(C-3),47.0(C-4),44.6(C-5),19.6(C-6),27.8(C-7),44.2(C-8),24.1(C-9),30.1(C-10),23.9(C-11),31.8(C-12),46.0(C-13),46.9(C-14),44.6(C-15),74.8(C-16),56.8(C-17),19.4(C-18),29.7(C-19),85.1(C-20),22.7(C-21),35.1(C-22),25.7(C-23),81.7(C-24),82.3m(C-25),28.6(C-26),22.9(C-27),19.1(C-28),19.1(C-29),19.1(C-30),21.6及び22.5(酢酸群のメチル),170.4及び170.3(酢酸群のカルボニル).
4.5mLのピリジン中の301mgの化合物Inを、99mgのNH2OH・HClと、撹拌下において還流温度で1時間にわたって反応させた。その後、反応混合物を、100gの氷を含むフラスコに注ぎ、及びAcOEt(3×)で抽出した。有機相を10%HCl溶液、続いて水で繰り返し洗浄し、且つその後、減圧下で乾燥及び濃縮した。蒸発後に得られた残渣をカラムクロマトグラフィーによって精製して277mgのオキシムId(90%)を得た。P.f.200~205℃.IR(KBr)Vmax cm-1:3379.8,2968.9,2870.9,1638.5,1460,1380.1,1103.9.EM-IE m/z(%):487(M+,13),470(9),452(9),286(8),143(100),125(21),59(10).RMN 1H(300MHz,CDCl3)δppm:0.54(d,J=4.2,1H,H-19),0.74(d,J=4.2,1H,H-19’),0.88(s,3H,CH3),1.1(s,6H,2CH3),1.3(s,3H,CH3),1.3(s,3H,CH3),1.4(s,3H,CH3),3.38(dq,1H),3.9(t,J=1.8,J=7.8,1H,H-24),4.6(m,1H,H-16).RMN 13C(75.4MHz)δppm:32.7(C-1),20.0(C-2),167.1(C-3),43.4(C-4),48.8(C-5),21.7(C-6),26.1(C-7),47.6(C-8),20.9(C-9),27.3(C-10),26.1(C-11),33.1(C-12),46.3(C-13),46.6(C-14),48.7(C-15),73.4(C-16),55.6(C-17),21.2(C-18),30(C-19),87.2(C-20),25.7(C-21),37.3(C-22),23.7(C-23),84.5(C-24),70.8(C-25),27.3(C-26),26.3(C-27),20.3(C-28),20.9(C-29),20.9(C-30).0.40×0.32×0.26mmの結晶を使用し、X線回折分析を実施した。前記分析は、Siemens P4回折計において293Kの温度で実施した。化合物の結晶学的データを表5に示す。X線回折分析の実験条件及び結果は、コードCCDC254670でCCDCに寄託した。
4mLの酢酸中の100mgのInの溶液を0~5℃において0.3mLの水中の三酸化クロム(100mg)で処理した。1時間後、混合物を室温で放置し、及びその後、AcOEt(3×)で抽出した。有機相を従来通りに処理して所望の生成物Ie(40%)を得た。P.f.138~140℃.IR(フィルム)Vmax cm-1:2972.73,2876.01,1768.64(C=O),1737.46(C=O),1703.84(C=O),1462.38,1385.8.EM-IE m/z(%):426(M+,100),411(23),313(35),288(34),270(15),99(42),43(27).RMN 1H(200MHz,CDCl3)δppm:0.68m(d,J=4.5,1H,H-19),0.88(d,J=4.5,1H,H-19’),1.07(s,3H,CH3),1.12(s,3H,CH3),1.13(s,3H,CH3),1.34(s,3H,CH3),1.49(s,3H,CH3).RMN 13C(75.5MHz)δppm:33.1(C-1),37.3(C-2),215.1(C-3),50.1(C-4),48.5(C-5),21.2(C-6),26.2(C-7),47.0(C-8),20.2(C-9),26.5(C-10),26.1(C-11),33.4(C-12),45.7(C-13),46.2(C-14),50.6(C-15),215.8(C-16),65.1(C-17),28.3(C-18),30.1(C-19),85.5(C-20),22.1(C-21),42.4(C-22),27.8(C-23),177.2(C-24),19.7(C-28),20.7(C-29),19.9(C-30).
200mgのIn、60.2mgの酢酸ナトリウム及び5mLの酢酸無水物の混合物を還流温度で18時間にわたって加熱した。その後、混合物を、50gの氷を含むエルレンマイヤーフラスコに注ぎ、及び15分間にわたって撹拌した。フラスコの内容物をAcOEt(3×)で抽出した。有機相を減圧下で乾燥及び濃縮して半固体を得た。前記生成物を再結晶化(ヘキサン/AcOEt)して、200~206℃の融点を有する対応する酢酸If(99%)を得た。IR(フィルム)cm-1 2971.49,2943.41,2872.45,1734.68(C=O),1706.33(C=O),1459.92,1368.46,1241.62.EM-IE m/z,(%):556(M+),496(24),436(27),395(28),185(52),143(42),125(100),43(57).RMN 1H(300MHz)CDCl3δppm:0.53(d,J=4.2,1H,H-19),0.83(d,J=4.2,1H,H-19’),0.96(s,3H,CH3-21),1.05(s,3H,CH3-29),1.09(s,3H,CH3-18),1.23(s,3H,CH3-26),1.40(s,3H,CH3-28),1.47(s,3H,CH3-27),1.55(s,3H,CH3-21),2.00(s,3H,CH3),2.02(s,3H,CH3),3.74(t,J=7.7,1H,H-24),5.39(m,1H,H-16).RMN 13C(300MHz,CDCl3):33.2(C-1),37.3(C-2),214.9(C-3),50.1(C-4),47.7(C-5),21.2(C-6),25.9(C-7),48.4(C-8),20.7(C-9),26.5(C-10),26.8(C-11),32.1(C-12),46.6(C-13),46.9(C-14),45.5(C-15),75.04(C-16),57.16(C-17)20.7(C-18),30.3(C-19),85.0(C-20),22.6(C-21),35.2(C-22),25.7(C-23),81.6(C-24),82.3(C-25),28.5(C-26),22.9(C-27),19.9(C-28),22.2(C-29),20.07(C-30),21.5,22.4,170.13,170.29.
6.5mLのピリジン中の200mgのIn二酢酸を、95mgのNH2OH・HClと、撹拌下において還流温度で1.5時間にわたって反応させた。その後、反応混合物を、50gの氷を含むフラスコに注ぎ、及びAcOEt(3×)で抽出した。有機相を10%HCl溶液と、その後、水とで3回洗浄した。有機相の再結晶化は、p.f.140~143℃からのIgオキシムの精製(90%)を可能にした。IR(フィルム)Vmax cm-1:3318.57,2972.66,2942.16,2872.86,1734.27,1456.29,1368.98,1242.09.EM-IE m/z(%):571(M+),511(12),434(15),185(67),143(49),125(100),43(60).RMN 1H(300MHz,CDCl3)δppm:0.44(d,J=4.2,1H,H-19),0.72(d,J=4.2,1H,H-19’),0.94(s,3H,CH3),1.08(s,3H,CH3),1.14(s,3H,CH3),1.22(s,3H,CH3),1.38(s,3H,CH3),1.47(s,3H,CH3),1.54(s,3H,CH3),2.00(s,3H,CH3),2.02(s,3H,CH3),2.52(d,J=8.4,1H,H-17),3.36(dc,1H),3.73(t,J=7.5,1H,H-24),5.38(m,1H,H-16),6.62(sa,1H,O-H).RMN 13C(75.5MHz)δppm:32.6(C-1),20.0(C-2),166.9(C-3),42.7(C-4),48.7(C-5),21.0(C-6),25.8(C-7),47.5(C-8),20.4(C-9),26.8(C-10),26.5(C-11),32.0(C-12),46.6(C-13),46.9(C-14),45.4(C-15),75.1(C-16),57.0(C-17),21.6(C-18),30.2(C-19),85.1(C-20),22.6(C-21),35.0(C-22),25.6(C-23),81.7(C-24),82.3(C-25),28.6(C-26),22.9(C-27),19.8(C-28),23.6(C-29),20.0(C-30),21.5及び22.5(酢酸群からのメチルの炭素),170.4及び170.3(酢酸群中のカルボニルに対応する炭素).
不活性雰囲気中に含有される、6mLの乾燥ピリジン中の200mgのInの溶液に1mLのギ酸エチル(新規に蒸留された)及び無水MeOH中の0.8mLのナトリウム溶液(0.44g/6ml)を添加した。反応を室温で一晩撹拌し続けた。黄褐色の外観及び/又は不溶性沈殿物の形成を反応の証拠とみなした。適切な時間後、反応混合物を27mLの水中の3mLの酢酸の冷却溶液中に入れた。上記作用の結果として、沈殿物の外観を観察し、それを塩化メチレンで抽出した。水相を廃棄した。有機相を水で洗浄し、及び2%水酸化カリウム溶液で抽出した。塩基性抽出物をエーテルで洗浄し、氷酢酸で酸性化し、及び最後に塩化メチレンで抽出した。最終的な塩化メチレン相を減圧下で乾燥及び濃縮して、不純な半固体生成物を得た。前記生成物を分取層クロマトグラフィーによって精製してホルミル化誘導体Ih(89%)を得た。IR(KBr)Vmax cm-1:3403.7,2974.0,2941.9,2874.8,1635.1,1586.9,1464.6,1355.9.EM-IE m/z(%):500(M+,2),482(6),441(M+-59,6),143(100),125(22),107(13),85(12),71(12),59(8),43(13).RMN 1H(200MHz,CDCl3)δppm:0.49(d,J=4.4,1H,H-19),0.70(d,J=4.4,1H,H-19’),0.92(s,3H,CH3),1.1(s,3H,CH3),1.15(s,3H,CH3),1.22(s,3H,CH3),1.26(s,3H,CH3),1.3(s,3H,CH3),1.46(s,3H,CH3),2.60(d,J=15,1H),3.46(sa,2H,2O-H),3.86(t,J=7.4,1H,H-24),4.63(m,1H,H-16),8.7(s,1H,H-31),14.8(sa,1H,O-H).RMN 13C(50MHz)δppm:33.1(C-1),106.6(C-2),190.5(C-3),42.7(C-4),48.5(C-5),21.4(C-6),26.1(C-7),44.7(C-8),19.3(C-9),29.7(C-10),25.5(C-11),31.8(C-12),46.3(C-13),46.6(C-14),48.6(C-15),73.5(C-16),55.6(C-17),21.2(C-18),30.2(C-19),87.2(C-20),25.2(C-21),37.3(C-22),23.7(C-23),84.5(C-24),70.9(C-25),27.3(C-26),26.1(C-27),20.6(C-28),24.4(C-29),21.6(C-30),188.9(C-31).
5mLの氷酢酸中の60mgのホルミル化誘導体Ihの溶液を撹拌下において30mgの塩酸ヒドロキシルアミンと還流温度で2時間にわたって反応させた。その後、反応混合物を、50gの氷を含むエルレンマイヤーフラスコに注ぎ、及びAcOEtで抽出した。有機相を5%炭酸水素ナトリウム溶液(3×)及び水で洗浄した。水相を廃棄した。有機相を減圧下で乾燥及び濃縮して、不純な半固体を得た。前記半固体をカラムクロマトグラフィーによって精製してイソオキサゾールIi(80%)を得た。P.f.125~129℃.IR(フィルム)Vmax cm-1:3377.57,2970.67,2940.45,2875.63,1640,1564.63,1463,1379.57.EM-IE m/z(%):497(M+,4),479(8),439(10),420(10),337(10),296(9),143(100),125(22),107(15),43(15).RMN 1H(300MHz,CDCl3)δppm:0.47(d,J=4.5,1H,H-19),0.74(d,J=4.5,1H,H-19’),0.94(s,3H,CH3),1.15(s,153H,CH3),1.21(s,3H,CH3),1.26(s,3H,CH3),1.30(s,3H,CH3),1.36(s,3H,CH3),1.46(s,3H,CH3),2.66(d,J=15.6,1H),3.87(t,J=7.2,1H,H-24),4.63(m,1H,H-16),7.98(s,1H).RMN 13C(75.4MHz)δppm:28.3(C-1),109.9(C-2),174.8(C-3),37.4(C-4),48.5(C-5),20.8(C-6),26.4(C-7),46.3(C-8),19.7(C-9),24.8(C-10),25.3(C-11),33.2(C-12),46.6(C-13),46.8(C-14),48.8(C-15),73.4(C-16),55.7(C-17),21.2(C-18),30.4(C-19),87.2(C-20),25.7(C-21),37.3(C-22),23.8(C-23),84.5(C-24),70.9(C-25),27.3(C-26),26.1(C-27),20.6(C-28),25.5(C-29),22.2(C-30),149.4(C-31).
CHCl3中に溶解された100mgのInオキシムに0.5mLのトリフルオロ酢酸無水物を0℃で徐々に添加した。添加が完了すると、反応混合物を25℃で18分間にわたって定常的な撹拌下に維持した。反応混合物を減圧下で蒸発させた。この反応から、In 16-トリフルオロアセトキシ-ラクタムとして同定される生成物を得た。メタノール中の炭酸カリウムの溶液を前記生成物に添加し、及びそれを室温で15分間にわたって撹拌し続け、その後、溶液を濾過し、及び溶媒を減圧下で蒸発させた。反応生成物を2:1のHex:AcOEtの極性のカラムクロマトグラフィーによって精製し、38mgのIjを得た。IR(CHCl3):Vmax cm-1:3612,3395,2963,2871,1644cm-1.EIMS m/z(%):487(M+,29.27),429(M+-58,5.4),428(11.5),413(64.86),58(100).HRMS:実測値m/z 488.3726,[M+H]+;C30H50NO4は、488.3739を必要とした.1H NMR(CDCl3,300MHz):d0.61(1H,d,J=6Hz,H-190),0.68(1H,d,J=6Hz,H-19),0.86(3H,s,H-29130)*,1.11(3H,s,H-18),1.21(3H,s,H-21),1.26(3H,s,H-27),1.30(3H,s,H-26),1.33(3H,s,H-29/30)*,3.1(1H,m,H-2),3.83(1H,t,J=7Hz,H-24),4.60(1H,m,H-16),7.5(1H,s,NH).13C NMR(75MHz,CDCl3):d20.2(C-18),20.3(C-28),21.0(C-6),21.0(C-9),22.1(C-29),23.9(C-23),24.4(C-30),25.3(C-21),26.5(C-7),26.5(C-10),26.7(C-11),27.0(C-26),27.5(C-27),29.5(C-1),29.9(C-2),30.8(C-19),33.0(C-12),36.2(C-22),45.5(C-14),45.9(C-13),48.2(C-5),48.5(C-8),50.08(C-15),55.5(C-4),56.3(C-17),69.4(C-25),71.5(C-16),83.4(C-24),85.6(C-20),175.6(C-3).
事前に得られた且つ不活性雰囲気下の0.15mmolの塩化ヘキサデカノイルに0.22mmolのInを添加し、4mLの乾燥ジクロロメタンに溶解した。反応を30分間にわたって撹拌させた。この時点後、15mLの酢酸エチルを反応混合物に添加し、及びそれを分液漏斗に入れた。有機相を蒸留水で3回及びNaHCO3の飽和溶液で3回洗浄し、減圧下において、無水Na2SO4で乾燥させ、及び濃縮した。反応混合物を、シリカを充填したオープンカラムクロマトグラフィーにかけた。溶出混合物としてヘキサン-酢酸エチル混合物(7:3)を使用した。画分3~8から50mgの白色非晶質固体をp.f.246℃、70%の収率で得た。IR(CHCl3溶液)cm-1:2920.70,2851.35(CH),1732.60(C=O),1707.92(C=O),1463.77,1379.20,1270.56,1153.83.EM-FAB+ m/z(%):948(1),933(5),437(77),381(34),125(100),43(93).EM-IE(70eV), m/z,(%):692[M+-パルミチン酸](6),436(24),381(22),256(22),125(100),43(54).RMN 1H(300MHz,CDCl3)δppm:5.44(1H,ddd J=5.4,J=2.7 y J=12.3Hz,H-16),3.66(1H,dd,J=6.9Hz及びJ=8.51Hz,H-24),1.38(3H,s),1.25(m,パルミチン酸塩残基の2群のCH3及びいくつかのCH2の場合),1.14(3H,s),1.09(3H,s),1.04(3H,s),0.87(3H,s),0.81(1H,d,J=4.3Hz,H-19a),0.59(1H,d,J=4.3Hz,H-19b).RMN 13C(75MHz,CDCl3)δppm:215.68(C3),175.46及び172.91(パルミチン酸エステルのカルボニル),81.91(C24),81.89(C25),74.45(C16),56.35(C17),49.58(C4),47.84(C8),47.15(C5),46.15(C13),46.02(C14),44.91(C15),35.97(C2),36.80(C22),33.64(C1),32.64(C12),29.56(C19),29.54(パルミチン酸塩残基からのメチレン),29.01(C20),26.30(C11),25.88(C7),27.90(C26),27.36(C27),24.40(C23),21.61(C21),21.61(C18),20.19(C29),19.63(C30),14.07(パルミチン酸メチル).
EtOH中の100mgのIeの溶液を289mgの水酸化カリウムとともに40分間にわたって還流に維持した。反応の中和後、70mgの3,16-ジオキソ-25-ノル-シクロアルタン-17-エン-24-オイック酸[I’a]を得た。P.f.182~184℃.IR(KBr):Vmax cm-1:3327,1741,1703,1615cm-1.EIMS m/z(%):426(M+,39.69),411(100),143(4.5),125(3).HRMS:実測値m/z 427.2864,[M+H]+;C27H39O4は、427.2848を必要とした。1H NMR(300MHz,CDCl3):δppm:0.64(d,J=4.2Hz,1H,H-19),0.86(d,J=4.8Hz,1H,H-190),0.99(s,3H,CH3),1.06(s,3H,CH3),1.11(s,3H,CH3),1.35(s,3H,CH3),1.92(s,3H,CH3).13C NMR(75MHz,CDCl3):δppm:20.2(C-18),20.7(C-28),20.8(C-30),20.9(C-9),21.2(C-29),22.1(C-21),22.6(C-6),26.0(C-7),26.3(C-11),26.3(C-10),29.2(C-23),30.6(C-19),30.8(C-22),32.6(C-12),33.1(C-1),37.2(C-2),42.3(C-13),45.7(C-14),47.9(C-8),48.2(C-5),50.20(C-4),51.0(C-15),141.7(C-17),149.5(C-20),177.8(C-24),207.3(C-16),216.0(C-3).
Claims (22)
- インビボ動物モデルにおける健常リンパ球細胞に対して細胞傷害性又は遺伝毒性を呈しない、式(I)及び(I’)の、
アルジェンタチンA及びC、
イソアルジェンチンB、及び
アルジェンタチンD
と称されるグアユリン化合物A、B、C及びDにおいて、老化プロセスを通して抗炎症活性を呈し、がん細胞の成長を阻害することを特徴とするグアユリン化合物A、B、C及びDであって、
式(I):
(A)-(B)-(C)
(式中、
Aは、
の1つから選択される基であり、
Bは、
であり、及び
Cは、
の1つから選択される基であり、
ここで、R1は、
から選択される基を表し、
R2は、
から選択される基を表し、
R3は、
から選択される基を表し、
R4は、-OH、
から選択される基を表し、
R1及びR3は、同時に、
であり得、
R3及びR4は、同時に、-OH又は-OAcであり得、
R1及びR2は、同時に、それぞれ
及び-Brであることはなく、
R5は、H、CH3又はアルキル鎖の1つから選択される基であり、
Aが、
であるとき、R1は、
ではなく、且つR2は、-Brではなく、且つR3及びR4は、同時に、-OH又は-OAcから選択される基であり、
Cが、
であるとき、R1及びR3は、同時に=Oであり得、及びR2は、-Brではないか、又は
Aが、
であるとき、R1及びR2は、一緒に、基
を形成し得る)
の前記化合物並びに上記の前記化合物の鏡像異性体、ジアステレオ異性体、鏡像異性体の混合物、ジアステレオ異性体の混合物、アノマー、水和物、溶媒和物、多形体及びその薬学的に許容できる塩であり、及び
式(I’):
(A)-(B)-T
(式中、
A及びBは、上記で定義された意味を有し、
R1は、=O、
から選択される基を表し、
R2は、
から選択される基を表し、
R3は、
から選択される基を表し、
R1及びR3は、同時に=Oであり得、
R1及びR2は、同時に、それぞれ
及び-Brであることはなく、
R5は、H、CH3又はアルキル鎖の1つから選択される基であり、
Aが、
であるとき、R1は、
ではなく、及びR2は、-Brではなく、
Aが、
であるとき、R1及びR2は、一緒に、基
を形成し得、Tは、基
を表す)
の前記化合物並びに上記の前記化合物の鏡像異性体、ジアステレオ異性体、鏡像異性体の混合物、ジアステレオ異性体の混合物、アノマー、水和物、溶媒和物、多形体及びその薬学的に許容できる塩である、グアユリン化合物A、B、C及びD。 - 式(I):
(A)-(B)-(C)
(式中、A、B、R1、R2、R3、R4及びR5は、請求項1に従って定義される)
のグアユリン化合物において、
R3及びR4は、同時に-OHであり得ず、及び
R1及びR2は、同時に、それぞれ=O及び-Hであることはない、
ことを特徴とするグアユリン化合物並びに上記の前記化合物の鏡像異性体、ジアステレオ異性体、鏡像異性体の混合物、ジアステレオ異性体の混合物、アノマー、水和物、溶媒和物、多形体及びその薬学的に許容できる塩。 - 請求項1に記載の、式(I’):
(A)-(B)-T
(式中、A及びBは、上記で定義された意味を有する)
のグアユリン化合物において、
R1は、=O、
から選択される基を表し、
R2は、
から選択される基を表し、
R3は、
から選択される基を表し、
R1及びR3は、同時に=Oであり得、
R1及びR2は、同時に、それぞれ
及び-Brであることはなく、
R5は、H、CH3又はアルキル鎖の1つから選択される基であり、
Aが、
であるとき、R1は、
ではなく、及びR2は、-Brではなく、
Aが、
であるとき、R1及びR2は、一緒に、基
を形成し得、Tは、基
を表すことを特徴とする、
グアユリン化合物並びに上記の前記化合物の鏡像異性体、ジアステレオ異性体、鏡像異性体の混合物、ジアステレオ異性体の混合物、アノマー、水和物、溶媒和物、多形体及びその薬学的に許容できる塩。 - 前記化合物(Ih)の合成は、不活性雰囲気中に含有される、6mlの乾燥ピリジン中の200mgのInの溶液に1mlのギ酸エチル(新規に蒸留された)、無水MeOH中の0.8mlのナトリウム溶液(0.44g/6ml)が添加され、反応が、撹拌下で室温において、黄褐色の外観及び/又は不溶性沈殿物の形成まで8~12時間にわたって維持され、その後、反応混合物が27mlの水中の3mlの酢酸の冷却溶液中に入れられ、前記沈殿物が塩化メチレンで抽出され、有機相が水で洗浄され、及び2%水酸化カリウム溶液で抽出され、塩基性抽出物がエーテルで洗浄され、氷酢酸で酸性化され、及び最後に塩化メチレンで抽出され、最終的な塩化メチレン相が減圧下で乾燥及び濃縮されて、不純な半固体生成物が得られ、分取層クロマトグラフィーによって精製して前記ホルミル化誘導体Ihが得られるステップ
に従って実施されることを特徴とする、
請求項5に記載のグアユリン化合物。 - 前記化合物(Ij)の合成は、CHCl3に溶解された100mgのInオキシムに0.5mLのトリフルオロ酢酸無水物が0℃で徐々に添加され、反応混合物が25℃で18分間にわたって常に撹拌され、その後、前記反応混合物が減圧下で蒸発され、前記反応からInの16-トリフルオロアセトキシ-ラクタムが得られ、メタノール中の炭酸カリウムの溶液が添加され、及び室温で15分間にわたって撹拌され、前記溶液が、その後、濾過され、及び溶媒が減圧下で蒸発され、反応生成物が2:1のHex:AcOEtの極性のカラムクロマトグラフィーによって精製され、Ijが得られるステップ
に従って実施されることを特徴とする、
請求項10に記載のグアユリン化合物。 - 前記化合物(Im)の合成は、事前に得られた且つ不活性雰囲気下の0.15mmolの塩化ヘキサデカノイルに0.22mmolのInが添加され、4mlの乾燥ジクロロメタンに溶解され、前記反応が30分間にわたって撹拌され、その後、15mLの酢酸エチルが添加され、及びそれが分液漏斗に入れられ、有機相が蒸留水で3回及びNaHCO3の飽和溶液で3回洗浄され、減圧下において、無水Na2SO4で乾燥され、及び濃縮され、反応混合物が、シリカを充填したオープンカラムクロマトグラフィーにかけられ、使用された溶出混合物がヘキサン-酢酸エチル(7:3)であり、画分3~8から白色非晶質固体(Im)が得られるステップ
に従って実施されることを特徴とする、
請求項5に記載のグアユリン化合物。 - ヒトがん細胞株中で炎症性プロセスに干渉し、及び抗腫瘍活性を有する活性化合物であることを特徴とする、
請求項1~20のいずれか一項に記載のグアユリン化合物。 - 前記グアユリン化合物が、健常細胞に対して細胞傷害性をもたらすことなく、抗腫瘍効果を発揮する機構は、細胞老化の誘発を通したものであることを特徴とする、
請求項1~21のいずれか一項に記載のグアユリン化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXMX/A/2019/006749 | 2019-06-10 | ||
MX2019006749A MX2019006749A (es) | 2019-06-10 | 2019-06-10 | Compuestos activadores de senescencia celular. |
PCT/MX2020/050010 WO2020251346A1 (es) | 2019-06-10 | 2020-06-10 | Compuestos activadores de senescencia celular |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022536698A true JP2022536698A (ja) | 2022-08-18 |
JPWO2020251346A5 JPWO2020251346A5 (ja) | 2023-09-04 |
Family
ID=73781643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021573470A Pending JP2022536698A (ja) | 2019-06-10 | 2020-06-10 | 細胞老化活性化化合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220233553A1 (ja) |
EP (1) | EP3988521A4 (ja) |
JP (1) | JP2022536698A (ja) |
MX (1) | MX2019006749A (ja) |
WO (1) | WO2020251346A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240059800A1 (en) * | 2020-12-18 | 2024-02-22 | Bridgestone Corporation | Modified guayule resin product and related processes |
EP4288443A1 (en) * | 2021-02-08 | 2023-12-13 | Bridgestone Corporation | Modified guayule resin product and related processes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2548880T3 (pl) | 2003-06-23 | 2019-07-31 | Telomerase Activation Sciences, Inc. | Kompozycje powodujące wzrost aktywności telomerazy |
PT2437606T (pt) | 2009-05-18 | 2016-09-22 | Telomerase Activation Sciences Inc | Composições e processos para aumentar a atividade da telomerase |
-
2019
- 2019-06-10 MX MX2019006749A patent/MX2019006749A/es unknown
-
2020
- 2020-06-10 WO PCT/MX2020/050010 patent/WO2020251346A1/es unknown
- 2020-06-10 JP JP2021573470A patent/JP2022536698A/ja active Pending
- 2020-06-10 EP EP20822864.3A patent/EP3988521A4/en active Pending
- 2020-06-10 US US17/618,348 patent/US20220233553A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220233553A1 (en) | 2022-07-28 |
EP3988521A1 (en) | 2022-04-27 |
MX2019006749A (es) | 2022-11-28 |
EP3988521A4 (en) | 2023-07-05 |
WO2020251346A1 (es) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wolfram et al. | Homopiperazine-rhodamine B adducts of triterpenoic acids are strong mitocans | |
Csuk et al. | Synthesis and antitumor activity of ring A modified glycyrrhetinic acid derivatives | |
CN103619865B (zh) | 某些化学个体、组合物及方法 | |
JP2022536698A (ja) | 細胞老化活性化化合物 | |
HU230128B1 (hu) | Kiválasztott kondenzált pirrolokarbazolok | |
JP2009530405A (ja) | 合成五環性トリテルペノイド、ならびにベツリン酸およびベツリンの誘導体 | |
JP2012232997A (ja) | シクロパミンアナログ及びその使用方法 | |
JPH06501962A (ja) | アンドロスタン及びプレグナン系列の構成要素によるgaba受容体のアロステリック修飾のための方法、組成物及び化合物 | |
JPS63500661A (ja) | 新規ビタミンd類似体 | |
EA030907B1 (ru) | Аналоги кортистатина, их синтез и применения | |
US20060234956A1 (en) | Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof | |
Lee et al. | Marliolide inhibits skin carcinogenesis by activating NRF2/ARE to induce heme oxygenase-1 | |
JP2021535183A (ja) | C19骨格およびステロイドならびにそれらの使用および製造方法 | |
Guo et al. | Synthesis, characterization and biological evaluation of some 16E-arylidene androstane derivatives as potential anticancer agents | |
D'yakonov et al. | Catalytic cyclometallation in steroid chemistry V: Synthesis of hybrid molecules based on steroid oximes and (5Z, 9Z)-tetradeca-5, 9-dienedioic acid as potential anticancer agents | |
JP6606806B2 (ja) | 重水素化キナゾリノン化合物及び該化合物を含む薬物組成物 | |
CA3190144A1 (en) | Naphthalene monoimide compounds and methods thereof | |
CN110981882B (zh) | 一类白屈菜碱一氧化氮供体衍生物及其制备方法和用途 | |
EP1765826A2 (en) | Novel antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles | |
JP2015506929A (ja) | 神経保護剤及び抗炎症剤として作用するスピロステロイド系 | |
EP1594886B1 (de) | Antitumor wirksame 2-substituierte d-homoestra-1,3,5(10)-trien-3-yl sulfamate | |
CN107602518B (zh) | 香豆素-二硫代氨基甲酸酯衍生物及其合成方法 | |
CN106946974B (zh) | 一类含吡唑杂环的熊果酰胺衍生物及其合成与应用 | |
Komissarova et al. | New Conjugates of Betulin with 2-Aminoethanesulfonic Acid | |
CN115160399B (zh) | 一种皂皮酸类化合物及其制备方法和医用用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230612 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230612 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230824 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240305 |